Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites
NCT ID: NCT03963947
Last Updated: 2023-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
97 participants
OBSERVATIONAL
2019-06-01
2023-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Cat Dander
NCT04207697
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
NCT05395689
Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Alternaria Alternata
NCT03604718
Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac® Hausstaubmilbe
NCT03127436
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
NCT03821077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients receive a rush schedule administration every month for a year. They attend at least 5 study visits to inform about the adverse reactions, the self reported symptoms and the medication intake.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Beltavac® Polymerized with house dust mites
Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive skin testing
* Positive Serum-Specific IgE determination
* Parental or legal representative informed consent
* Clinical sintomatology on the inclusion period
Exclusion Criteria
* Patients suffering from uncontrolled and severe asthma
* Patients with a known autoimmune disease
* Patients with active malignant disease
* Patients requiring beta-blockers
* Patients having any contraindication for the use of adrenaline
* Patients with previous immunotherapy with this allergen or another allergen with cross-reaction
* Patients with immunotherapy treatment at the time of inclusion
3 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Probelte Pharma S.L.U.
INDUSTRY
Alfons Malet i Casajuana
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alfons Malet i Casajuana
Head of Allergy Service in Teknon Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teknon Medical Center
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAL-BEL-2018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.